Detalhe da pesquisa
1.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335217
2.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
3.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072323
4.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602290
5.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
6.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593565
7.
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Oncologist
; 25(1): e109-e119, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31575788
8.
Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
J Med Genet
; 56(3): 195-198, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29535157
9.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Int J Gynecol Cancer
; 29(9): 1396-1404, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685558
10.
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(2): 400, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36697966
11.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
12.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
13.
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.
Oncology
; 91(1): 48-54, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27256106
14.
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Cancer
; 120(2): 262-70, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24399418
15.
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
JAMA Oncol
; 9(5): 675-682, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36928279
16.
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
J Clin Oncol
; 40(34): 3952-3964, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658487
17.
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Nat Commun
; 12(1): 2487, 2021 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941784
18.
Early oncology clinical trial design in the era of molecular-targeted agents.
Future Oncol
; 6(8): 1339-52, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20799878
19.
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
ESMO Open
; 5(6): e001081, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33262202
20.
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Clin Pharmacol Drug Dev
; 8(1): 107-118, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29799676